MedTrace Logo

Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder

NCT00457899 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2007-11-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether increasing the amount (dose) of quetiapine IR (immediate release formulation) more rapidly than conventional dose increases, improves the control of symptoms as measured by the Positive and Negative Syndrome Scale (PANSS) - a psychiatric assessment scale that measures both positive and negative symptoms - in patients with acute schizophrenia or schizoaffective disorder.

Conditions

Interventions

DRUG

Quetiapine IR (Immediate Release)

oral

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca UK Medical Director, MD · AstraZeneca UK

  • Professor Gary Sullivan, MD · St Tydfil's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Completion
2007-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00457899 on ClinicalTrials.gov